Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease

118Citations
Citations of this article
148Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer's disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minimally invasive tools for AD diagnostics. In the present study, the recently developed Multimer Detection System (MDS) for AD, a new enzyme-linked immunosorbent assay for measuring Aβ oligomers selectively, was used to detect Aβ oligomers in the plasma of patients with AD and healthy control individuals. Methods: Twenty-four patients with AD and 37 cognitively normal control individuals underwent extensive clinical evaluations as follows: blood sampling; detailed neuropsychological tests; brain magnetic resonance imaging; cerebrospinal fluid (CSF) measurement of Aβ42, phosphorylated tau protein (pTau), and total tau protein (tTau); and 11C-Pittsburgh compound B (PIB) positron emission tomography. Pearson's correlation analyses between the estimations of Aβ oligomer levels by MDS and other conventional AD biomarkers (CSF Aβ42, pTau, and tTau, as well as PIB standardized uptake value ratio [PIB SUVR]) were conducted. ROC analyses were used to compare the diagnostic performance of each biomarker. Results: The plasma levels of Aβ oligomers by MDS were higher in patients with AD than in normal control individuals, and they correlated well with conventional AD biomarkers (levels of Aβ oligomers by MDS vs. CSF Aβ42, r = -0.443; PIB SUVR, r = 0.430; CSF pTau, r = 0.530; CSF tTau, r = 0.604). The sensitivity and specificity of detecting plasma Aβ oligomers by MDS for differentiating AD from the normal controls were 78.3% and 86.5%, respectively. The AUC for plasma Aβ oligomers by MDS was 0.844, which was not significantly different from the AUC of other biomarkers (p = 0.250). Conclusions: Plasma levels of Aβ oligomers could be assessed using MDS, which might be a simple, noninvasive, and accessible assay for evaluating brain amyloid deposition related to AD pathology.

Cited by Powered by Scopus

887Citations
1588Readers

This article is free to access.

620Citations
802Readers
388Citations
712Readers

This article is free to access.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wang, M. J., Yi, S., Han, J. Y., Park, S. Y., Jang, J. W., Chun, I. K., … Kim, S. (2017). Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease. Alzheimer’s Research and Therapy, 9(1). https://doi.org/10.1186/s13195-017-0324-0

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘24‘25015304560

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 46

55%

Researcher 24

29%

Professor / Associate Prof. 11

13%

Lecturer / Post doc 2

2%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 24

31%

Medicine and Dentistry 22

29%

Neuroscience 21

27%

Agricultural and Biological Sciences 10

13%

Article Metrics

Tooltip
Mentions
News Mentions: 3
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free
0